MarketPeel
Insider Trading Intelligence
Pricing
…
DM

David C. Myles

OLMA
CH. DISCOV. & NON-CLIN DEV OFF · OLEMA PHARMACEUTICALS, INC. · CIK 0001831216
FILING MIX · LIFETIME36%/64%
BUYS
14
SELLS
25
TOTAL VALUE
$6.10M
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
250,000
AVG SELL PX
$23.25
TRADE KIND
SHOWING 39 / 39
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
20 backtested trades · 8 horizons · 24 pending
Forward-return performance of every backtestable P/S trade by David C. Myles, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d20+85.00%-7.74%-0.39%-7.35%-4.94%—
14d20+90.00%-10.96%+0.86%-11.81%-9.87%—
30d20+95.00%-16.21%+1.16%-17.37%-13.09%—
60d20+95.00%-27.57%+2.02%-29.60%-32.99%—
90d20+80.00%-30.32%+2.42%-32.75%-41.06%—
180d20(5 pending)+100.00%-44.18%+10.73%-54.90%-52.76%—
1y20(8 pending)+66.67%+38.48%+24.53%+13.95%-60.74%—
2y20(11 pending)+55.56%-2.86%+48.68%-51.54%-85.26%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OLMA · 250,000 shares · as of Feb 2, 2026
0156,100312,200468,299624,399202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 14 buys / 25 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
106,250——106,250Feb 2, 2026Feb 4, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
250,000——250,000Feb 2, 2026Feb 4, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
CH. DISCOV. & NON-CLIN DEV OFF
50,000$4.87$243.5K592,761Jan 14, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
35,003$28.99$1.01M542,761Jan 14, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
14,997$28.60$428.9K577,764Jan 14, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
50,000——50,000Jan 14, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
50,000——100,000Jan 13, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
200$28.49$5.7K542,761Jan 13, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
49,800$27.60$1.37M542,961Jan 13, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
CH. DISCOV. & NON-CLIN DEV OFF
50,000$4.87$243.5K592,761Jan 13, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
10,000$28.34$283.4K144,846Jan 12, 2026Jan 14, 2026 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
43,729$30.40$1.33M557,927Dec 19, 2025Dec 23, 2025 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
1,225$28.08$34.4K601,656Dec 19, 2025Dec 23, 2025 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
6,046$31.39$189.8K551,881Dec 19, 2025Dec 23, 2025 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALEGRANT
Gift
9,000——542,881Dec 19, 2025Dec 23, 2025 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
205,000——205,000Feb 28, 2025Mar 3, 2025 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
13,314$8.66$115.3K598,633Dec 11, 2024Dec 11, 2024 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
300$9.39$2.8K598,333Dec 11, 2024Dec 11, 2024 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
12,452$9.38$116.8K611,947Dec 10, 2024Dec 11, 2024 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
48,750——624,399Dec 9, 2024Dec 11, 2024 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
195,000——195,000Feb 1, 2024Feb 5, 2024 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
6,653$13.89$92.4K574,099Nov 22, 2023Nov 22, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
6,776$14.87$100.8K580,952Nov 21, 2023Nov 22, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CH. DISCOV. & NON-CLIN DEV OFF
200$15.32$3.1K580,752Nov 21, 2023Nov 22, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
26,250——587,728Nov 20, 2023Nov 22, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
200$17.61$3.5K561,270Nov 8, 2023Nov 13, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
541$17.51$9.5K561,470Nov 3, 2023Nov 3, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,332$15.36$51.2K562,011Nov 2, 2023Nov 3, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,668$15.02$100.2K565,343Nov 1, 2023Nov 3, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,000$12.67$253.4K572,011Sep 19, 2023Sep 21, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Feb 1, 2023Feb 2, 2023 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
118,750——118,750Feb 1, 2022Feb 3, 2022 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
CHIEF DEVELOPMENT OFFICER
10,000$10.30$103.0K582,901Dec 10, 2021Dec 13, 2021 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
Chief Development Officer
12,831——12,831Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
Chief Development Officer
154,846——154,846Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
Chief Development Officer
154,846——0Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
Chief Development Officer
12,831——0Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
179,340——179,340Nov 18, 2020Nov 19, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
143,472——591,821Jun 15, 2020Nov 19, 2020 ↗View →
Other insiders · OLMA
Loading peer insiders…
About this filer
CIK 0001831216
ROLE
CH. DISCOV. & NON-CLIN DEV OFF
PRIMARY
OLMA
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001831216DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback